The abstract is read at the publisher; the summary is JClub's.
Nivolumab plus axitinib in untreated advanced mucosal melanoma achieved a 45% objective response rate (RECIST v1.1) in 20 evaluable Western patients.
- Why it matters: Mucosal melanoma has inferior outcomes with immunotherapy, and VEGF signaling may contribute to immune resistance, creating a need for more effective first-line options.
- What they did: In a single-center phase II trial, patients received nivolumab every 4 weeks plus axitinib twice daily, with a phase Ib cohort adding ipilimumab or SBRT at progression.
- The result: Responses lasted a median 21 months, with median progression-free survival of 6.4 months; grade 3–5 treatment-related adverse events occurred in 67%, and triplet escalation was feasible.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.